Senores Pharmaceuticals Limited has submitted its Monitoring Agency Report for the quarter ended December 31, 2025, concerning the utilization of its Initial Public Offer (IPO) proceeds. The report, issued by CARE Ratings Limited, confirms that there were no deviations from the stated objects of the IPO, which aggregated to ₹500.00 crore. The Audit Committee reviewed the report on January 20, 2026, and the Board of Directors subsequently took it on record. The report is also available on the company's website, www.senorespharma.com. Key details from the report indicate that while most objectives are on track, there were minor delays in the completion of certain objectives, such as the repayment of borrowings by a subsidiary and funding working capital for subsidiaries, which were extended by the management committee. The total utilization of IPO proceeds as of December 31, 2025, stands at ₹362.12 crore, with ₹137.88 crore unutilized, primarily deployed in fixed deposits with HDFC Bank and ICICI Bank, earning an average return of approximately 7.05% on invested amounts. The utilization of funds for General Corporate Purposes (GCP) includes capex at API plant and Branded Generic Division Centre, loans to subsidiaries for capex and loan repayments, and repayment of the company's own loan.
